BioCryst Announces Leadership Transition
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), located in Research Triangle Park, has made significant leadership changes recently. Jon Stonehouse, the company’s president and CEO, has announced his retirement, set for December 30. As the company prepares for this transition, they have appointed Charlie Gayer, who currently serves as the chief commercial officer, to step into the role of president effective August 1.
Charlie Gayer: A Proven Leader
Charlie Gayer has been a pivotal figure in BioCryst, instrumental in the commercial success of ORLADEYO (berotralstat), which has introduced a groundbreaking treatment for hereditary angioedema. His efforts have significantly contributed to the company’s revenue growth, with estimates suggesting peak sales could reach $1 billion. As he transitions to CEO on January 1, 2026, he will also join the board of directors.
In a statement, Nancy Hutson, chair of the board, expressed gratitude towards Jon Stonehouse for his contributions, praising him for transforming BioCryst into a commercially successful and profitable enterprise. The board’s succession planning included a comprehensive evaluation of both internal and external candidates, highlighting Gayer's qualifications as uniquely aligned with the company's mission and growth trajectory.
Words from Jon Stonehouse
Jon Stonehouse expressed confidence in Charlie Gayer, stating, “He has a proven track record of delivering results and is largely responsible for one of the best commercial launches of a drug for a rare disease in recent history.” Stonehouse emphasized that Gayer truly understands the importance of the culture at BioCryst and is well-prepared to lead the company forward.
Gayer himself acknowledged the substantial impact of Stonehouse’s leadership, noting the patient-centered culture that has been fostered during his tenure. “Under his guidance, BioCryst has matured significantly, generating increasing revenue through ORLADEYO while advancing a promising pipeline,” Gayer remarked. This transition represents an exciting chapter for BioCryst, filled with opportunities for innovation and growth.
Gayer's Journey in BioCryst and Beyond
Before becoming CCO in January 2020, Gayer joined BioCryst in 2015 as vice president of global strategic marketing. His extensive experience includes leadership roles in competitive rare disease markets at Talecris Biotherapeutics and contributions to the marketing team after Grifols acquired Talecris. He began his career as a strategic consultant within the biopharmaceutical sector, which has equipped him with a robust understanding of the industry.
Gayer holds a B.A. in Politics from Princeton University and an M.B.A. from Duke University’s Fuqua School of Business, both of which complement his extensive experience and insight into the life sciences sector.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, based in the heart of the biotechnology hub, is fully committed to enhancing the lives of individuals battling hereditary angioedema and other rare diseases. With a rich history in structure-guided drug design, BioCryst is at the forefront of developing innovative therapies, including ORLADEYO, the first oral and once-daily plasma kallikrein inhibitor. The company is dedicated to advancing its pipeline of small-molecule and protein therapies, reflecting its mission to deliver life-changing solutions to patients.
Frequently Asked Questions
What role will Charlie Gayer take on at BioCryst?
Charlie Gayer will succeed Jon Stonehouse as the CEO of BioCryst Pharmaceuticals, effective January 1, 2026.
What has Gayer achieved at BioCryst prior to his CEO appointment?
Prior to becoming CEO, Gayer successfully led the commercialization of ORLADEYO, significantly growing the company’s revenue.
What impact has Jon Stonehouse had on BioCryst?
Jon Stonehouse has transformed BioCryst into a profitable commercial entity, establishing a strong foundation for future growth.
What is the company’s primary focus?
BioCryst focuses on developing therapies for hereditary angioedema and other rare diseases using innovative drug design techniques.
How can I learn more about BioCryst Pharmaceuticals?
For more information, you can visit their official website or follow them on LinkedIn.
